Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality

Journal of the American College of Cardiology

Volumn 41, Issue 11, 2003, Pages 2029-2035

  Kittleson, Michelle ^a   Hurwitz, Shelley ^a   Shah, Monica R ^a   Nohria, Anju ^a   Lewis, Eldrin ^a   Givertz, Michael ^a   Fang, James ^a   Jarcho, John ^a   Mudge, Gilbert ^a   Stevenson, Lynne Warner ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CREATININE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; HYDRALAZINE; INOTROPIC AGENT; LOOP DIURETIC AGENT; NITRATE; SODIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE;

ADULT; AGED; ANGIONEUROTIC EDEMA; ARTICLE; COUGHING; DEATH; DISEASE COURSE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; FEMALE; FOLLOW UP; HEART FAILURE; HEART TRANSPLANTATION; HOSPITAL ADMISSION; HOSPITAL DEPARTMENT; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HUMAN; HYPEREOSINOPHILIA; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEDICAL DOCUMENTATION; MORTALITY; OUTCOMES RESEARCH; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SYMPTOM; SYSTOLIC BLOOD PRESSURE; TASTE DISORDER; TREATMENT FAILURE;

EID: 0038313209     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00417-0     Document Type: Article

References (35)

1. Cleland JG, Dargie HJ, Ball SG, et al. Effects of enalapril in heart failure: a double-blind study of effects on exercise performance, renal function, hormones, and metabolic state. Br Heart J 1985;54:305-12.
2. Erhardt L, MacLean A, Ilgenfritz JU, Gelperin K, Blumenthal M, for the Fosinopril Efficacy/Safety Trial (FEST) Study Group. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Eur Heart J 1995;16:1892-9.
3. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
4. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
5. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-35.
6. Hunt SA. Guidelines for the evaluation and management of heart failure. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2001;38:2101-13.
7. Krumholz HM, Wang Y, Parent EM, Mockalis J, Petrillo M, Radford MJ. Quality of care for elderly patients hospitalized with heart failure. Arch Intern Med 1997;157:2242-7.
8. The Large State Peer Review Organization Consortium. Heart failure treatment with angiotensin-converting enzyme inhibitors in hospitalized Medicare patients in 10 large states. Arch Intern Med 1997;157:1103-8.
9. Nohria A, Chen YT, Morton DJ, Walsh R, Vlasses PH, Krumholz HM. Quality of care for patients hospitalized with heart failure at academic medical centers. Am Heart J 1999;137:1028-34.
10. Havranek EP, Abrams F, Stevens E, Parker K. Determinants of mortality in elderly patients with heart failure. Arch Intern Med 1998;158:2024-8.
11. Clinical Quality Improvement Network Investigators. Mortality risk and patterns of practice in 4606 acute care patients with congestive heart failure. Arch Intern Med 1996;156:1669-73.
12. Edep ME, Shah NB, Tateo IM, Massie BM. Differences between primary care physicians and cardiologists in management of congestive heart failure: relation to practice guidelines. J Am Coll Cardiol 1997;30:518-26.
13. Stafford RS, Saglam D, Blumenthal D. National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure. Arch Intern Med 1997;157:2460-4.
14. McDermott MM, Feinglass J, Lee P, et al. Heart failure between 1986 and 1994: temporal trends in drug-prescribing practices, hospital readmissions, and survival at an academic medical center. Am Heart J 1997;134:901-9.
15. Os I, Bratland B, Dahlof B, Gisholt K, Syvertsen JO, Tretli S. Female sex as an important determinant of lisinopril-induced cough. Lancet 1992;339:372.
16. Kostis JB, Shelton BJ, Yusuf S, et al., for the Studies of Left Ventricular Dysfunction Investigators. Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. Am Heart J 1994;128:358-64.
17. Kostis JB, Shelton B, Gosseliin G, et al., for the SOLVD Investigators. Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction. Am Heart J 1996;131:350-5.
18. Shah MR, Granger CB, Bart BA, et al. Sex-related differences in the use and adverse effects of angiotensin-converting enzyme inhibitors in heart failure: the study of patients intolerant of converting enzyme inhibitors registry. Am J Med 2000;109:489-92.
19. Cohn JN, Tognoni G, for the Valsartan Heart Failure Trial Investigators. A randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667-75.
20. Pitt B, Zannad F, Remme WJ, et al., for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709-17.
21. The MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomized intervention trialin congestive heart failure. Lancet 1999;353:2001-7.
22. Packer M, Kessler PD, Gottlieb SS. Adverse effects of converting-enzyme inhibition in patients with severe congestive heart failure: pathophysiology and management. Postgrad Med J 1986;62:179-82.
23. Uretsky BF, Sheahan RG. Primary prevention of sudden cardiac death in heart failure: will the solution be shocking? J Am Coll Cardiol 1997;30:1589-97.
24. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-9.
25. Madsen BK, Hansen JF, Stokholm KH, Brons J, Husum D, Mortensen LS. Chronic congestive heart failure. Description and survival of 190 consecutive patients with a diagnosis of chronic congestive heart failure based on clinical signs and symptoms. Eur Heart J 1994;15:303-10.
26. Spinar J, Vitovec J, Spac J, Blaha M, Spinarova L, Toman J. Noninvasive prognostic factors in chronic heart failure. One-year survival of 300 patients with a diagnosis of chronic heart failure due to ischemic heart disease or dilated cardiomyopathy. Int J Cardiol 1996;56:283-8.
27. The PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1999;325:1468-75.
28. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure. Circulation 1986;73:257-66.
29. Califf RM, Adams KF, McKenna WJ, et al. A randomized control trial of therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997;134:44-54.
30. Pulignano G, Del Sindaci D, Tavazzi L, et al. Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am Heart J 2002;143:46-55.
31. Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of the left ventricular systolic dysfunction. J Am Coll Cardiol 2001;38:421-8.
32. Stevenson LW, Couper G, Natterson P, et al. Target heart failure populations for newer therapies. Circulation 1995;2:174-81.
33. Bart BA, Ertl G, Held P, et al. Contemporary management of patients with left ventricular systolic dysfunction. Eur Heart J 1999;20:1182-90.
34. Bart BA, Gattis WA, Diem SJ, O'Connor CM. Reasons for underuse of angiotensin-converting enzyme inhibitors in patients with heart failure and left ventricular dysfunction. Am J Cardiol 1997;79:1118-20.
35. Saxon LA, Stevenson WG, Middlekauff HR, Stevenson LW. Increased risk of progressive hemodynamic deterioration in advanced heart failure patients requiring permanent pacemakers. Am Heart J 1993;125:1306-10.